Business context and reporting period
InnovAge Holding Corp. operates PACE programs, providing comprehensive care to frail seniors under capitated Medicare, Medicaid and other arrangements. At March 31, 2022, it served approximately 6,800 participants through 18 centers in five states. The supplied filing is a Form 10-Q for the quarter ended March 31, 2022 (fiscal third quarter), not 2021 Q3 as indicated in the request metadata.
Financial performance and liquidity
Amounts below are in millions of dollars unless noted.
| Metric | Three months ended March 31, 2022 | Three months ended March 31, 2021 | Nine months ended March 31, 2022 | Nine months ended March 31, 2021 |
|---|---|---|---|---|
| Total revenue | $177.4 | $156.3 | $525.8 | $466.2 |
| Operating income (loss) | $(6.7) | $(5.4) | $7.9 | $(23.0) |
| Net income (loss) | $(3.2) | $(10.9) | $5.6 | $(51.1) |
| Net income (loss) attributable to InnovAge | $(2.8) | $(10.5) | $6.2 | $(50.5) |
| Basic and diluted EPS | $(0.02) | $(0.09) | $0.05 | $(0.42) |
| Adjusted EBITDA (non-GAAP) | $1.9 | $20.3 | $34.9 | $66.0 |
Quarterly revenue grew 13.5%, primarily from higher capitation rates and 3.4% growth in member months. However, external provider costs rose 37.0%, reflecting increased outpatient, specialist, inpatient and housing costs; cost of care also increased with center reopenings, pre-opening costs and higher wages. The quarter’s operating loss widened year over year despite a smaller net loss, helped by lower interest expense and a tax benefit. For the nine-month period, revenue increased 12.8%, but center-level contribution margin fell to $111.7 million, or 21.3% of revenue, from $126.0 million, or 27.0%. Adjusted EBITDA and its margin declined to $34.9 million and 6.6%, from $66.0 million and 14.2%.
For the nine months, operating cash flow was $24.1 million, versus cash used of $17.0 million a year earlier. Investing used $23.6 million, including $20.1 million for property and equipment. Financing used $4.7 million. Cash, cash equivalents and restricted cash ended at $199.5 million. At March 31, current assets were $250.4 million and current liabilities $94.4 million. Debt totaled $74.5 million before unamortized issuance costs; the $100 million revolver was undrawn, with $2.6 million of letters of credit, and the company reported covenant compliance. Capital lease obligations totaled $13.5 million, current and noncurrent combined.
Material changes versus the prior comparable period
- Revenue increased, but medical/provider costs grew faster, compressing contribution margin and Adjusted EBITDA.
- Nine-month results improved from a substantial prior-year loss to net income. Comparisons are affected by prior-year IPO, Apax transaction and debt-refinancing items, including option-cancellation and transaction costs, debt-extinguishment losses, a Sacramento consolidation gain and contingent-consideration income.
- Interest expense fell substantially following lower debt balances and rates. Nine-month corporate, general and administrative expense also declined, largely because the prior-year period included Apax-related charges; current-period staffing, compliance, legal and public-company costs increased.
- The company restated prior-period presentation of redeemable noncontrolling interests, reclassifying approximately $17.0 million from permanent to temporary equity. Management concluded the prior-period error was not material.
Outlook, risks and unusual items
No specific financial guidance or quantified forecast is provided. Management expects ongoing investment and expense growth in absolute dollars, including public-company, compliance, audit, remediation, legal, technology and center-development costs. It stated that cash and operating cash flows should fund needs for at least 12 months, while cautioning that assumptions may prove incorrect. Planned expansion is constrained: CMS and state agencies suspended new enrollments at Sacramento and Colorado centers; California paused assurances for new centers pending remediation; Kentucky withdrew its intention to contract; CMS denied the Indiana application; and the company paused remaining Florida de novo steps. San Bernardino and Albuquerque audits also presented potential further regulatory exposure.
Colorado and federal DOJ False Claims Act investigations seek records concerning billing, services, referrals, audits and care quality; the company says it is cooperating and cannot predict outcomes. A putative IPO-related securities class action and an April 2022 stockholder books-and-records demand are also pending. Management said current proceedings were not expected, based on available information, to have a material adverse effect overall, but outcomes could affect individual periods. Further sanctions, repayment obligations, fines, enrollment restrictions or exclusion from government programs could materially harm growth and results.
COVID-19 effects and supply-chain disruption have raised medical supply costs; labor shortages and wage inflation, participant medical utilization, interest rates and general inflation are additional risks. Management reported no goodwill impairment after a quantitative assessment that incorporated sustained impacts from enrollment suspensions and constrained expansion, but warned that changed assumptions or further regulatory actions could lead to future impairment. Disclosure controls were reported effective as of March 31, 2022, with no material quarterly change in internal control over financial reporting.
Important facts for investors to verify
- Progress and validation of Colorado and Sacramento corrective-action plans, status of enrollment suspensions, and outcomes of the San Bernardino and Albuquerque audits.
- Developments in the DOJ and Colorado Medicaid investigations, securities litigation and stockholder demand, including any potential financial exposure or required disclosures.
- Whether rising provider costs, utilization and wages continue to outpace capitation-rate and enrollment growth; track contribution margin and Adjusted EBITDA alongside GAAP results.
- Cash generation, capital spending, debt service and covenant compliance, including sensitivity to variable interest rates and the company’s liquidity assumptions.
- Whether restricted growth affects goodwill valuation, planned centers and longer-term enrollment targets; no quantified guidance is provided in this filing.